NZ518167A - Composition comprising an alpha-amylase inhibitor, inulin, fructooligosaccharides and a fat inhibitor for treating obesity and preventing weight gain or causing weight loss - Google Patents

Composition comprising an alpha-amylase inhibitor, inulin, fructooligosaccharides and a fat inhibitor for treating obesity and preventing weight gain or causing weight loss

Info

Publication number
NZ518167A
NZ518167A NZ518167A NZ51816700A NZ518167A NZ 518167 A NZ518167 A NZ 518167A NZ 518167 A NZ518167 A NZ 518167A NZ 51816700 A NZ51816700 A NZ 51816700A NZ 518167 A NZ518167 A NZ 518167A
Authority
NZ
New Zealand
Prior art keywords
inhibitor
alpha
composition
treating obesity
fructooligosaccharides
Prior art date
Application number
NZ518167A
Other languages
English (en)
Inventor
Nils Mortensen
Original Assignee
Med Eq As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Med Eq As filed Critical Med Eq As
Publication of NZ518167A publication Critical patent/NZ518167A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
NZ518167A 1999-09-08 2000-09-08 Composition comprising an alpha-amylase inhibitor, inulin, fructooligosaccharides and a fat inhibitor for treating obesity and preventing weight gain or causing weight loss NZ518167A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921229.2A GB9921229D0 (en) 1999-09-08 1999-09-08 Compositions
PCT/GB2000/003472 WO2001017369A1 (en) 1999-09-08 2000-09-08 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of 'fast sugars'

Publications (1)

Publication Number Publication Date
NZ518167A true NZ518167A (en) 2003-03-28

Family

ID=10860574

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ518167A NZ518167A (en) 1999-09-08 2000-09-08 Composition comprising an alpha-amylase inhibitor, inulin, fructooligosaccharides and a fat inhibitor for treating obesity and preventing weight gain or causing weight loss

Country Status (14)

Country Link
EP (1) EP1213972B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003508467A (cg-RX-API-DMAC7.html)
KR (1) KR100594520B1 (cg-RX-API-DMAC7.html)
AT (1) ATE238689T1 (cg-RX-API-DMAC7.html)
AU (1) AU777044B2 (cg-RX-API-DMAC7.html)
CA (1) CA2383720A1 (cg-RX-API-DMAC7.html)
DE (1) DE60002484T2 (cg-RX-API-DMAC7.html)
DK (1) DK1213972T3 (cg-RX-API-DMAC7.html)
ES (1) ES2199174T3 (cg-RX-API-DMAC7.html)
GB (2) GB9921229D0 (cg-RX-API-DMAC7.html)
NO (1) NO314922B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ518167A (cg-RX-API-DMAC7.html)
PT (1) PT1213972E (cg-RX-API-DMAC7.html)
WO (1) WO2001017369A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2426552C2 (ru) * 2005-12-22 2011-08-20 Индена С.П.А. Экстракты phaseolus vulgaris, их применение и композиции, содержащие их

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601528B1 (en) 2000-12-23 2009-10-13 Elan Pharmaceuticals, Inc. Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7217556B1 (en) 2000-12-23 2007-05-15 Pfizer Inc Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US7384773B1 (en) 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US6797287B2 (en) 2001-09-25 2004-09-28 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
US7108869B2 (en) 2002-11-07 2006-09-19 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
ITMI20030391A1 (it) * 2003-03-04 2004-09-05 S I I T S R L Servizio Internaz Ionale Imballa Formulazioni anticarie a base di faseolamina.
JP5285852B2 (ja) * 2006-12-28 2013-09-11 株式会社ファンケル Dfaiiiの製造方法及びdfaiii高含有植物エキス
US20100330137A1 (en) * 2008-03-10 2010-12-30 Mauro Mantovani High bioavailability formulation of mangosteen and manufacturing process thereof
CN102292093B (zh) * 2009-02-02 2015-01-28 莱拉营养食品有限公司 用于代谢综合症控制的选自绒毛戴星草和莽吉柿的混合物
JP2011079752A (ja) * 2009-10-05 2011-04-21 Kracie Home Products Ltd 膵リパーゼ阻害剤並びにそれを含有する飲食品組成物及び医薬品組成物
CN103478738B (zh) * 2013-09-17 2016-02-10 深圳太太药业有限公司 一种具有减肥塑身及体重管理作用的组合物
EP3193899A1 (en) * 2014-09-19 2017-07-26 Nestec S.A. Methods and formulations for reducing absorption of carbohydrates in a companion animal
CN106036342A (zh) * 2016-06-14 2016-10-26 安徽平唐微食疗科技有限公司 适合于糖尿病人群食用的膳食补充固体饮料及其制备方法
IT201700078389A1 (it) * 2017-07-13 2019-01-13 Mv Medical Solutions Composizione utile nella prevenzione o trattamento degli stati di malassorbimento secondari a chirurgia bariatrica in soggetti obesi.
EP3975755A1 (en) * 2019-05-24 2022-04-06 Cosucra Groupe Warcoing S.A. Composition comprising inulin and protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010258A (en) * 1974-03-15 1977-03-01 Ajinomoto Co., Inc. Microbial amylase inhibitor and preparation thereof with the use of streptomyces diasticus var. amylostaticus
JP2757405B2 (ja) * 1988-12-09 1998-05-25 日清製粉株式会社 小麦から得られるα−アミラーゼインヒビターを含有するダイエット剤
US5612039A (en) * 1994-03-14 1997-03-18 Nini E. Policappelli Dietary supplement
JP2002535288A (ja) * 1999-01-22 2002-10-22 ウンツァ ディ マリア カルメラ マラッツィータ エッセ.ア.エッセ. リポタンパク質複合体およびそれらを含む組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2426552C2 (ru) * 2005-12-22 2011-08-20 Индена С.П.А. Экстракты phaseolus vulgaris, их применение и композиции, содержащие их

Also Published As

Publication number Publication date
NO314922B1 (no) 2003-06-16
AU7026900A (en) 2001-04-10
KR100594520B1 (ko) 2006-07-19
GB2364498A (en) 2002-01-30
PT1213972E (pt) 2003-09-30
AU777044B2 (en) 2004-09-30
ATE238689T1 (de) 2003-05-15
DE60002484D1 (de) 2003-06-05
CA2383720A1 (en) 2001-03-15
ES2199174T3 (es) 2004-02-16
NO20021160L (no) 2002-03-27
EP1213972A1 (en) 2002-06-19
JP2003508467A (ja) 2003-03-04
KR20020045605A (ko) 2002-06-19
DK1213972T3 (da) 2003-08-18
GB9921229D0 (en) 1999-11-10
EP1213972B1 (en) 2003-05-02
NO20021160D0 (no) 2002-03-08
WO2001017369A1 (en) 2001-03-15
GB0127158D0 (en) 2002-01-02
DE60002484T2 (de) 2004-03-18

Similar Documents

Publication Publication Date Title
YU30700A (sh) Kombinacija inhibitora aldozo reduktaze i inhibitora glikogen fosforilaze
MY133569A (en) Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
ATE269054T1 (de) Konfekt zusammensetzungen
CY2495B1 (en) Sulfonamides.
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
AU6040001A (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
MXPA04002751A (es) Modificacion del comportamiento de alimentacion.
NZ510677A (en) Use of glycogen phosphorylase inhibitors for the prophylactic treatment of type 2 diabetes mellitus
FI950369A0 (fi) Hedelmöitettyjä kuorellisia munia käsittävä koostumus
LTIP555A (en) Orally adminsterable drugs for the treatmentof central dopamine deficiency conditions
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
WO2000053149A3 (en) Method and composition for administering a cyclooxygenase-2 inhibitor
WO2001081332A3 (en) 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
BG104135A (en) Diabetes treatment with thiazolydindion, a form increasing the insulin and biguanide secretion
UA43317C2 (uk) Ароматичні похідні карбонової кислоти та фармацевтична композиція
ATE210149T1 (de) Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden
DK1213972T3 (da) Komposition omfattende en alfa-amylase-inhibitor og mindst en fysiologisk acceptabel forbindelse, der kan nedsætte absorptionen af "hurtigere sukkere" i tarmen
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
MY135840A (en) Crystals of an oxyiminoalkanoic acid derivative and their use as antidiabetics
WO2001035902A3 (en) Stabilized thyroxine compounds
AU2420001A (en) Methods and compositions for the treatment of pain
PL1694320T3 (pl) Zastosowanie kompozycji zawierających kwas oleanolowy i kwas ursolowy do wytwarzania leku do leczenia nadwrażliwości i nadreaktywności
MD670G2 (ro) Remediu cu acţiune imunomodulatoare
AU2566101A (en) Compounds and methods for the treatment of pain
MY123805A (en) Stabilized pharmaceutical composition based on quinupristine and dalfopristine and their preparation.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed